It is a randomized, single-blind clinical trial, whose population to be studied will be randomized patients with a diagnosis of dehiscence and infection of a cesarean surgical wound who meet the inclusion and exclusion criteria. H0: Sucrose does not reduce hospital days in patients with surgical wound dehiscence. HA: Sucrose reduces hospital days in patients with surgical wound dehiscence.
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Changes of in-hospital days
Timeframe: from the first intervention to delayed primary closure (by third intention), on average less than 14 days